Hyperice Introduces Hypervolt Go 2 as Everyday Wellness Essential for All
Hyperice, a global high-performance wellness brand, today introduced a new and improved version of its original, award-winning handheld massage gun, the Hypervolt Go. Leveling up and standing on its own within the percussive massage category, the newly redesigned, lightweight and versatile Hypervolt Go 2 is the most sophisticated portable percussion massager to hit the wellness market and is built to increase people’s range of motion with just a five minute treatment each day1.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005376/en/
Hyperice Introduces Hypervolt Go 2 as Everyday Wellness Essential for All (Photo: Business Wire)
The Hypervolt Go 2 adds to the company’s range of powerful percussion devices including the recently launched Hypervolt 2 and Hypervolt 2 Pro, all of which help everyday users and pro athletes alike massage away stress and muscle tension from the palm of their hand.
“For over 10 years, Hyperice has been relentlessly focused on developing innovative products to help people across the globe move and live better. The new Hypervolt Go 2 offers a unique combination of performance and portability for the wellness-minded consumer,” said Jim Huether, CEO of Hyperice. “Designed for the everyday go-getter, the Hypervolt Go 2 is a wellness essential - perfect for everyone who is moving at home or on the road and wants to be at their best everyday.”
“The Hypervolt Go 2 is the result of our 'design first’ approach to creating a product that looks as good as it feels. We wanted to design a product that people would want to take and use everywhere they go,” said Anthony Katz, Founder and President of Hyperice. “With this newest addition to the Hypervolt family, the Hypervolt Go 2 offers more choice, to more people, in more places than ever before.”
WELLNESS THAT MOVES WITH YOU
The new Hypervolt Go 2 has a sophisticated design that features minimalistic looks with an arctic-grey finish and feels great in your hand and on your body. It is built to last, with high-quality materials and intuitive ergonomics. The Hypervolt Go 2 is designed to move conveniently wherever users are headed and includes features such as:
- Patented QuietGlide® technology for near silent operation
- Improved airflow and ventilation
- New LED speed sensors and back button control
- New ergonomic handle
- Battery level LED band
- Three speeds of powerful percussion
Go behind the design of the Hypervolt Go 2.
Katz continued: “Our mission from the beginning, was to put a percussion device in as many hands as possible. To do that, we need to continue to design products that are accessible to the widest possible audience of users. We also know, with the world opening back up, people are constantly on the move, and space can oftentimes be limited, so the smaller you can make the device, the more places you can take it, the more you can use it. Hypervolt Go 2 represents the next step towards achieving that goal.”
“My current phase of my career is about longevity and maintaining a competitive advantage,” said Kelly Slater, 11-time World Surf League champion and Hyperice Athlete-Investor. “To be my best when I’m competing, I have to also feel great no matter where I am, which is why I never leave home without the Hypervolt Go 2. It’s the ultimate in portability, it’s dead silent and it comes in clutch whether I’m preparing for a major event or just managing everyday aches.”
The Hypervolt Go 2 retails for $199 (£199; €229) and is now available in North America and other select regions. For more information, visit hyperice.com. To purchase, please visit country-specific sites: Canada, France, Germany, Italy, Portugal, Spain, UK and the United States.
To learn more about the Hypervolt Go 2, visit hyperice.com.
INTRODUCING: THE GO COLLECTIVE
To amplify the ethos of the Go line, Hyperice has assembled a diverse collection of individuals within #TeamHyperice who represent different industries and backgrounds who are pushing the boundaries of what it means to ‘go get it.’ The Go Collective seeks to make a movement out of movement across the many dimensions of fitness, fashion, lifestyle, sports, travel, longevity, wellness, art, family, and more. Through expansive storytelling and involvement in community initiatives and events, Hyperice hopes the Go Collective will inspire individuals everywhere to prioritize their daily wellness.
Meet the inaugural Go Collective members:
- Robin Arzón, Head Instructor and VP of Fitness Programming at Peloton
- Tony Finau, PGA TOUR Golfer
- Adrianne Ho, Model and Founder of Sweat The Style & The Farmers Market Global
- Joe Holder, Nike Master Trainer and Founder of The Ocho System™
- Alix Klineman, Beach Volleyball Olympic Gold Medalist
- Kelly Slater, Professional Surfer
- Nigel Sylvester, Pro BMX Athlete and Content Creator
- Raven B. Varona (Ravie B), Professional Photographer
“I’m proud to be a member of Hyperice’s new Go Collective because it represents a community for people who show up everyday for themselves and for others,” said Robin Arzón, Head Instructor and VP of Fitness Programming at Peloton. “I believe there is transformative power in movement and as a mom, wife and athlete, being able to be at my best in all dimensions of my life is what motivates me to ‘go get it’. Hyperice’s suite of products, and the Hypervolt Go 2 in particular, are my go-to wellness tools that help me be at my best each and every day.”
“I take my role as a husband and father of five even more seriously than my career as a pro golfer. There’s no doubt staying healthy is a huge part of my commitment to performance, but more importantly, it’s critical to me that I’m the best version of myself whenever I’m spending valuable time with my family,” said Tony Finau, PGA TOUR player and Hyperice investor. “The Hypervolt Go 2 goes with me everywhere – on the course during competition, training and recovery, and when I’m traveling between tournaments – to ensure that I can push to the limits of my full potential for years to come.”
“When it comes to feeling your best, a major part of that is making sure to move and to move effectively everyday, and recovery is a critical component of a holistic approach to an individual’s overall wellness,” said Joe Holder, Nike Master Trainer and Founder of The Ocho System™. “As someone who gets the opportunity to help so many people unlock their personal version of wellness, the Hypervolt Go 2 is an incredible tool for anyone to utilize to help ensure they can come back day after day - ready to be anything but average.”
To join the Go Collective community, follow Hyperice on social - instagram.com/hyperice and twitter.com/hyperice and sign up for emails on hyperice.com to unlock exclusive content, special offers, access to events and more. Learn more at: hyperice.com/newsroom/go-collective
About Hyperice
Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com.
1 Journal of Sports Science & Medicine 2020
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005376/en/
Contact information
Media Contact:
Jack Taylor PR
Nadine Hachicho
hyperice@jacktaylorpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom